WMIF MAIN SITE

2024 COMING SOON

Thomas Schuetz, MD, PhD

Thomas J. Schuetz, MD, PhD has over 20 years of experience in oncology, biopharmaceutical drug development, and life science venture investing. He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. While at OrbiMed, Thomas also co-founded Audentes Therapeutics, where he served as a director until its acquisition by Astellas. While at OrbiMed, he worked on the investments in Enobia Pharma, Relypsa, and Arteaus Therapeutics, and served as a director at each of those companies. Thomas has multiple years of clinical strategy, development, and operations experience, including roles as chief medical officer of Therion Biologics Corporation, a cancer vaccine company, and as vice president of clinical affairs at Transkaryotic Therapies, a company acquired by Shire.
Thomas completed his medical training at Massachusetts General Hospital, where he served as the chief medical resident. He completed a medical oncology fellowship at the Dana-Farber Cancer Institute. Thomas holds a BS in chemistry and a MD from Harvard Medical School, and a PhD in genetics from Harvard University. Thomas is board certified in medical oncology.

CEO & Co-Founder, Compass Therapeutics

Subscribe

Join our email list to recieve exclusive offers

Opt In